GB2276624B - Inactivation of cytotoxic drugs in the vascular compartment of a host - Google Patents
Inactivation of cytotoxic drugs in the vascular compartment of a hostInfo
- Publication number
- GB2276624B GB2276624B GB9410237A GB9410237A GB2276624B GB 2276624 B GB2276624 B GB 2276624B GB 9410237 A GB9410237 A GB 9410237A GB 9410237 A GB9410237 A GB 9410237A GB 2276624 B GB2276624 B GB 2276624B
- Authority
- GB
- United Kingdom
- Prior art keywords
- inactivation
- host
- cytotoxic drugs
- vascular compartment
- vascular
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
- A61K47/67—Enzyme prodrug therapy, e.g. gene directed enzyme drug therapy [GDEPT] or VDEPT
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6957—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a device or a kit, e.g. stents or microdevices
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Nanotechnology (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Heart & Thoracic Surgery (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Genetics & Genomics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9410237A GB2276624B (en) | 1992-01-09 | 1993-01-11 | Inactivation of cytotoxic drugs in the vascular compartment of a host |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB929200415A GB9200415D0 (en) | 1992-01-09 | 1992-01-09 | Inactivation of cytotoxic drugs |
GB929204104A GB9204104D0 (en) | 1992-01-09 | 1992-02-26 | Inactivation of cytotoxic drugs |
GB9410237A GB2276624B (en) | 1992-01-09 | 1993-01-11 | Inactivation of cytotoxic drugs in the vascular compartment of a host |
PCT/GB1993/000040 WO1993013806A1 (en) | 1992-01-09 | 1993-01-11 | Inactivation of cytotoxic drugs |
Publications (3)
Publication Number | Publication Date |
---|---|
GB9410237D0 GB9410237D0 (en) | 1994-07-27 |
GB2276624A GB2276624A (en) | 1994-10-05 |
GB2276624B true GB2276624B (en) | 1995-10-25 |
Family
ID=26300132
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GB929200415A Pending GB9200415D0 (en) | 1992-01-09 | 1992-01-09 | Inactivation of cytotoxic drugs |
GB929204104A Pending GB9204104D0 (en) | 1992-01-09 | 1992-02-26 | Inactivation of cytotoxic drugs |
GB9410237A Expired - Fee Related GB2276624B (en) | 1992-01-09 | 1993-01-11 | Inactivation of cytotoxic drugs in the vascular compartment of a host |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GB929200415A Pending GB9200415D0 (en) | 1992-01-09 | 1992-01-09 | Inactivation of cytotoxic drugs |
GB929204104A Pending GB9204104D0 (en) | 1992-01-09 | 1992-02-26 | Inactivation of cytotoxic drugs |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0620742A1 (en) |
JP (1) | JPH07506339A (en) |
CA (1) | CA2124217A1 (en) |
GB (3) | GB9200415D0 (en) |
WO (1) | WO1993013806A1 (en) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5264220A (en) * | 1991-11-12 | 1993-11-23 | Long David M Jr | Method of extending the vascular dwell-time of particulate therapeutic and particulate diagnostic agents |
GB9323429D0 (en) * | 1993-11-12 | 1994-01-05 | Wellcome Found | Therapy |
GB9624993D0 (en) * | 1996-11-30 | 1997-01-15 | Aepact Ltd | Tumour therapy |
GB9712370D0 (en) | 1997-06-14 | 1997-08-13 | Aepact Ltd | Therapeutic systems |
ATE346036T1 (en) * | 1998-05-22 | 2006-12-15 | Abbott Lab | ANTIANGIOGENIC SUBSTANCE FOR THE TREATMENT OF CANCER, ARTHRITIS AND RETINAL DISEASES |
CO5170498A1 (en) * | 1999-05-28 | 2002-06-27 | Abbott Lab | BIARIL SULFONAMIDS ARE USEFUL AS CELL PROLIFERATION INHIBITORS |
FR2883873B1 (en) * | 2005-03-31 | 2009-07-10 | Pharmamens Sarl | AGE INHIBITORS |
US7732309B2 (en) * | 2006-12-08 | 2010-06-08 | Applied Materials, Inc. | Plasma immersed ion implantation process |
AU2011288464B2 (en) * | 2010-08-10 | 2015-10-29 | Glycotope Gmbh | Fab-glycosylated antibodies |
EP4257611A3 (en) | 2018-05-18 | 2024-03-06 | Glycotope GmbH | Anti-muc1 antibody |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1988007378A1 (en) * | 1987-03-09 | 1988-10-06 | Cancer Research Campaign Technology Ltd. | Improvements relating to drug delivery systems |
EP0308208A1 (en) * | 1987-09-14 | 1989-03-22 | Center For Molecular Medicine And Immunology | Modified antibody conjugates with enhanced clearance |
WO1989010140A1 (en) * | 1988-04-22 | 1989-11-02 | Cancer Research Campaign Technology Limited | Further improvements relating to drug delivery systems |
WO1990009134A1 (en) * | 1989-02-13 | 1990-08-23 | Cosgrove James H | Device for releasably supporting a plurality of objects |
WO1990010460A1 (en) * | 1989-03-13 | 1990-09-20 | Kenneth Naoyuki Matsumura | Method for reducing side effects of a drug |
EP0506124A1 (en) * | 1991-03-27 | 1992-09-30 | Tanox Biosystems, Inc. | Methods and substances for recruiting therapeutic agents to solid issues comprising two single chain VH-VL bifunctional binding molecules |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991009134A1 (en) * | 1989-12-15 | 1991-06-27 | Takeda Chemical Industries, Ltd. | Biospecific antibody to cancer cell and enzyme with prodrug-activating characteristics |
-
1992
- 1992-01-09 GB GB929200415A patent/GB9200415D0/en active Pending
- 1992-02-26 GB GB929204104A patent/GB9204104D0/en active Pending
-
1993
- 1993-01-11 JP JP5512252A patent/JPH07506339A/en active Pending
- 1993-01-11 GB GB9410237A patent/GB2276624B/en not_active Expired - Fee Related
- 1993-01-11 CA CA002124217A patent/CA2124217A1/en not_active Abandoned
- 1993-01-11 WO PCT/GB1993/000040 patent/WO1993013806A1/en not_active Application Discontinuation
- 1993-01-11 EP EP93901821A patent/EP0620742A1/en not_active Ceased
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1988007378A1 (en) * | 1987-03-09 | 1988-10-06 | Cancer Research Campaign Technology Ltd. | Improvements relating to drug delivery systems |
EP0308208A1 (en) * | 1987-09-14 | 1989-03-22 | Center For Molecular Medicine And Immunology | Modified antibody conjugates with enhanced clearance |
WO1989010140A1 (en) * | 1988-04-22 | 1989-11-02 | Cancer Research Campaign Technology Limited | Further improvements relating to drug delivery systems |
WO1990009134A1 (en) * | 1989-02-13 | 1990-08-23 | Cosgrove James H | Device for releasably supporting a plurality of objects |
WO1990010460A1 (en) * | 1989-03-13 | 1990-09-20 | Kenneth Naoyuki Matsumura | Method for reducing side effects of a drug |
EP0506124A1 (en) * | 1991-03-27 | 1992-09-30 | Tanox Biosystems, Inc. | Methods and substances for recruiting therapeutic agents to solid issues comprising two single chain VH-VL bifunctional binding molecules |
Non-Patent Citations (2)
Title |
---|
Antibody,Immunoconjugates,Radiopharm. 1988,1(2),169-180 * |
Proc.Natl.Acad.Sci.USA 1983,80,3078-3080 * |
Also Published As
Publication number | Publication date |
---|---|
JPH07506339A (en) | 1995-07-13 |
GB2276624A (en) | 1994-10-05 |
GB9200415D0 (en) | 1992-02-26 |
GB9204104D0 (en) | 1992-04-08 |
WO1993013806A1 (en) | 1993-07-22 |
GB9410237D0 (en) | 1994-07-27 |
CA2124217A1 (en) | 1993-07-22 |
EP0620742A1 (en) | 1994-10-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GB9200417D0 (en) | Cytotoxic drug therapy | |
GB8820945D0 (en) | Medical articles | |
IL107411A0 (en) | Infusion administering catheter holder | |
EP0351687A3 (en) | Vascular catheter | |
AU4854393A (en) | Self-introducing infusion catheter | |
AU4227793A (en) | Drug infuser | |
HK1000279A1 (en) | Medical bag | |
AU7673694A (en) | Simultaneous angioplasty and drug delivery | |
ZA895909B (en) | Cytotoxic drug conjugates | |
AU8253791A (en) | Delivery catheter | |
ZA895908B (en) | Cytotoxic drug conjugates | |
GB2276624B (en) | Inactivation of cytotoxic drugs in the vascular compartment of a host | |
NZ257470A (en) | 5-hydrazino-quinolone derivatives and antimicrobial medicaments | |
HU00207A9 (en) | Sulfonanilide derivatives and medicine | |
AU7472994A (en) | Polyesters for use in blood partitioning | |
HUT57669A (en) | Auotmatic shelf container | |
GB9119793D0 (en) | Medicine containers | |
NZ248041A (en) | Aminoalkyl- tetrahydrofuran derivatives and medicaments | |
AU667546C (en) | Medicine container | |
GB9213627D0 (en) | Cholangiography catheter | |
GB9314472D0 (en) | Pharmaceutical container | |
GB9013977D0 (en) | Medicament container | |
GB9000627D0 (en) | Medicament container | |
IE883708L (en) | Medicament container | |
GB8821698D0 (en) | Medicament container |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PCNP | Patent ceased through non-payment of renewal fee |
Effective date: 20010111 |